Loading
A phase 3 trial testing Chiauranib in ovarian cancer, now recruiting.
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer is a phase 3 interventional study registered as NCT04921527, led by Chipscreen Biosciences, and recruiting on the registry. Official title: A Multi-centre, Double-blind, Randomised Phase III Clinical Trial of Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer. Planned enrolment is 454 participants (estimated). The study started in 2021-12-20 and primary completion is expected in 2024-12-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/